Harbinger Health Announces Results Demonstrating High-Sensitivity of Early Stage Multi-Cancer Detection Platform at ASCO Annual Meeting 2023

Overall sensitivity of early cancer detection for novel blood-based assay was 82% at 95% specificity; specific cancer detection rates include colorectal (96%), lung (85%), prostate (82%) and breast (73%) Results, which demonstrate the potential of Harbinger’s biology-informed, AI-driven approach, currently being validated in 10,000-subject CORE-HH clinical trial with the Sarah Cannon Research Institute Findings published … Read more